Tharimmune, Inc. completed a share sale transaction on August 27, 2025, which resulted in the company raising as much as $5.35 million. This capital infusion is a crucial financing event for the clinical-stage biotechnology company.
The proceeds from this share sale are intended to support Tharimmune's ongoing research and development activities and operational expenses. As a company with no current revenue, continuous capital raises are essential for its sustained operations.
This financing helps to address the company's liquidity challenges and enables the continued advancement of its innovative pipeline. It is a necessary step to fund the extensive R&D required for drug development.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.